175 related articles for article (PubMed ID: 10976550)
1. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
[TBL] [Abstract][Full Text] [Related]
2. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
3. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
4. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.
Skjelbo E; Mutabingwa TK; Bygbjerg Ib; Nielsen KK; Gram LF; Brøosen K
Clin Pharmacol Ther; 1996 Mar; 59(3):304-11. PubMed ID: 8653993
[TBL] [Abstract][Full Text] [Related]
5. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.
Hoskins JM; Shenfield GM; Gross AS
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):611-4. PubMed ID: 13680037
[TBL] [Abstract][Full Text] [Related]
6. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
7. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.
Hoskins JM; Shenfield GM; Gross AS
Br J Clin Pharmacol; 1998 Nov; 46(5):499-504. PubMed ID: 9833604
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
Jeppesen U; Rasmussen BB; Brøsen K
Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103
[TBL] [Abstract][Full Text] [Related]
9. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
10. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.
Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P
Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064
[TBL] [Abstract][Full Text] [Related]
11. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
[TBL] [Abstract][Full Text] [Related]
12. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
[TBL] [Abstract][Full Text] [Related]
16. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.
Kim MJ; Bertino JS; Gaedigk A; Zhang Y; Sellers EM; Nafziger AN
Clin Pharmacol Ther; 2002 Aug; 72(2):192-9. PubMed ID: 12189366
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2C19 genotype and proguanil oxidative polymorphism.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1997 Jun; 43(6):659-60. PubMed ID: 9205829
[TBL] [Abstract][Full Text] [Related]
18. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
Marinac JS; Balian JD; Foxworth JW; Willsie SK; Daus JC; Owen R; Flockhart DA
Clin Pharmacol Ther; 1996 Aug; 60(2):138-44. PubMed ID: 8823231
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
